European Journal of Cancer
Volume 43, Issue 16 , Pages 2339-2344 , November 2007

HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17

  • Rosalba Torrisi

      Affiliations

    • Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • Corresponding Author InformationCorresponding author: Tel.: +39 257489502/460; fax: +39 257489581.
    • ,
  • Nicole Rotmensz

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Vincenzo Bagnardi

      Affiliations

    • Division of Epidemiology and Biostatistics, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • Division of Senology, European Institute of Oncology, Ripamonti 435, 20141, Milan, Italy
    • ,
  • Giuseppe Viale

      Affiliations

    • Division of Pathology, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • University of Milan School of Medicine, via Festa del Perdono 7, 20135 Milan, Italy
    • ,
  • Barbara Del Curto

      Affiliations

    • Division of Pathology, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Patrizia Dell’Orto

      Affiliations

    • Division of Pathology, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Paolo Veronesi

      Affiliations

    • Division of Senology, European Institute of Oncology, Ripamonti 435, 20141, Milan, Italy
    • University of Milan School of Medicine, via Festa del Perdono 7, 20135 Milan, Italy
    • ,
  • Alberto Luini

      Affiliations

    • Division of Senology, European Institute of Oncology, Ripamonti 435, 20141, Milan, Italy
    • ,
  • Claudia D’Alessandro

      Affiliations

    • Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Anna Cardillo

      Affiliations

    • Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Aron Goldhirsch

      Affiliations

    • Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy
    • ,
  • Marco Colleoni

      Affiliations

    • Research Unit of Medical Senology at the Department of Medicine, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy

Received 19 February 2007 ,Revised 2 July 2007 ,Accepted 20 July 2007.

References 

  1. Ross JS, Fletcher JA, Bloom KJ, et al. Targeted therapy in breast cancer. Mol & Cell Proteomics. 2004;3:379–398
  2. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer are we there yet?. Am J Clin Pathol. 2004;121(S):33–49
  3. Bose S, Mohammed M, Shintaku P, Rao PN. Her-2/neu gene amplification in low to moderately expressing breast cancers: possible role of chromosome 17/Her-2/neu polysomy. The Breast J. 2001;7:337–344
  4. Vincent-Salomon A, McGrogan G, Couturier J, et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer : eesiults of the French Multicentre GEFIPCS Study. Histopathology. 2003;42:337–347
  5. Bilous M, Dowsett M, Hanna W, et al. Current perspectives on HER2 testing:a review of National Testing Guidelines. Mod Pathol. 2003;16:173–182
  6. Downs-Kelly E, Yoder BJ, Stoler M, et al. The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization study. Am J Surg Pathol. 2005;29:1221–1227
  7. Wang S, Saboorian H, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137–145
  8. Varshney D, Zhou YY, Geller SA, Alsabeh R. Determination of HER-2 status and chromosome 17 polysomy in breast carcinomas comparing HercepTest and PathVysion FISH assay. Am J Clin Pathol. 2004;121:70–77
  9. Colleoni M, Rotmensz N, Peruzzotti G, et al. Role of endocrine responsiveness and adjuvant therapy in very young women (below 35 years) with operable breast cancer and node negative disease. Ann Oncol. 2006;17:1497–1503
  10. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromsome 17 in breast cancer tumors showing an overexpression of ERBB2:a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res. 2005;7:267–273
  11. Goldhirsch A, Glick JH, Gelber RD, et al. International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005;16:1569–1583
  12. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science. 1987;235:177–182
  13. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103–112
  14. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res. 2003;9:1039–1046
  15. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol. 1992;10:1049–1056
  16. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792
  17. Wolff AC, Hammond EH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor receptor 2 testing in breast cancer. J Clin Oncol. 2006;25:118–145
  18. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240–246
  19. Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positive do not get the message. J Clin Oncol. 2001;19:2714–2721
  20. Hofmann M, Gaiser T, Kneitz H, et al. Comparison of chromigenic in-situ hybridization (CISH) with FISH and ICH for assessment of HER2 status and prediction of response to therapy: analysis from a study of trastuzumab monotherapy. Ann Oncol 2004, 15 (suppl 3) abs 520.
  21. Perez E, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol. 2006;24:3032–3038
  22. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–726
  23. Yaziji H, Gown AM. Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome?. Adv Anat Pathol. 2002;9:338–344
  24. Prati R, Apple SK, He J, Gornbein JA, Chang H. Histopathological characteristics predicting HER-2/neu amplification in breast cancer. Breast J. 2005;11:433–439
  25. Watters AD, Going JJ, Cooke TG, Bartlett JMS. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast Cancer Res Treat. 2003;77:109–114
  26. Ma Y, Lespagnard L, Durbecq V, et al. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on clinical practice. Clin Cancer Res. 2005;11:4393–4399
  27. Lal P, Salazar PA, Ladanyi M, Chen B. Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinomas without HER-2/neu gene amplification. J Mol Diagn. 2003;5:155–159
  28. Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2+ in immunohistochemical analysis. Eur J Cancer. 2006;42:1501–1506
  29. Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue –based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridiziation and immunohistochemistry. J Clin Oncol. 2000;18:3651–3664

PII: S0959-8049(07)00560-6

doi: 10.1016/j.ejca.2007.07.033

European Journal of Cancer
Volume 43, Issue 16 , Pages 2339-2344 , November 2007

Article Tools